ADVFN ADVFN

Wir konnten keine Ergebnisse für:
Stelle sicher, dass deine Schreibweise korrekt ist oder versuche deine Suche zu erweitern.

Trends

Toplisten

Es scheint, dass du nicht eingeloggt bist.
Klicke auf den Button unten, um dich einzuloggen und deine zuletzt angesehenen Aktien zu sehen.

Hot Features

Icon for alerts Registrieren Sie sich für Echtzeit-Benachrichtigungen, benutzerdefinierte Portfolios und Marktbewegungen.
TG Therapeutics Inc

TG Therapeutics Inc (TGTX)

50,54
0,24
(0,48%)
Geschlossen 17 Juni 10:00PM
49,67
-0,87
(-1,72%)
Nach Börsenschluss: 1:59AM

TG Therapeutics Inc (TGTX) Aktie

Professionelle Tools für Privatanleger.

Premium

Wichtige Statistiken und Details

Current Price
50,54
( 0,48% )
Gebot
49,17
Fragen
50,50
Volumen
1.993.362
49,00 Tagesbereich 50,7999
25,33 52-Wochen-Bereich 50,60
Marktkapitalisierung
Handelsende
50,30
Handelsbeginn
50,41
Letzte Trade
1
@
50.51
Letzter Handelszeitpunkt
Finanzvolumen
US$ 99.805.845
VWAP
50,0691
Durchschnittliches Volumen (3 Mio.)
US$ 2.175.799
Ausgegebene Aktien
141.723.008
Dividendenrendite (LTM)
Kurs-Gewinn-Verhältnis
17,25
Gewinn pro Aktie (EPS)
2,87
Erlöse (LTM)
700,35M
Nettogewinn (LTM)
461,9M

Über TG Therapeutics Inc

TG Therapeutics, Inc., a commercial stage biopharmaceutical company, focuses on the acquisition, development, and commercialization of novel treatments for B-cell mediated diseases in the United States and internationally. The company provides BRIUMVI, an anti-CD20 monoclonal antibody for the treatm... TG Therapeutics, Inc., a commercial stage biopharmaceutical company, focuses on the acquisition, development, and commercialization of novel treatments for B-cell mediated diseases in the United States and internationally. The company provides BRIUMVI, an anti-CD20 monoclonal antibody for the treatment of adult patients with relapsing forms of multiple sclerosis (RMS), including clinically isolated syndrome, relapsing-remitting disease, and active secondary progressive disease in adults. The company’s development pipeline comprises Ublituximab IV, glycoengineered anti-CD20 mAb for the treatment of relapsing MS; TG-1701 is an orally available and covalently bound Bruton’s tyrosine kinase (BTK) inhibitor that exhibits selectivity to BTK in vitro kinase screening; and TG-1801, a bispecific CD47 and CD19 antibody. Its research pipeline includes various investigational medicines. The company has license agreements with LFB Biotechnologies S.A.S; GTC Biotherapeutics; LFB/GTC LLC; Ildong Pharmaceutical Co. Ltd.; and Jiangsu Hengrui Medicine Co. The company was incorporated in 1993 and is based in Morrisville, North Carolina. Mehr anzeigen

Sektor
Healthcare
Branche
Biotechnology & Life Sciences
Hauptsitz
Morrisville, United States
Gegründet
1993
TG Therapeutics Inc is listed in the Healthcare sector of the NASDAQ with ticker TGTX. The last closing price for TG Therapeutics was US$50,30. Over the last year, TG Therapeutics shares have traded in a share price range of US$ 25,33 to US$ 50,60.

TG Therapeutics currently has 141.723.008 shares in issue. The market capitalisation of TG Therapeutics is US$7,16 billion. TG Therapeutics has a price to earnings ratio (PE ratio) of 17.25.

Option-Flow TG Therapeutics (TGTX)

Gesamtfluss

Bullisch

Nettoprämie

341k

Calls / Puts

400,00%

Käuf. / Verkä.

125,00%

OTM / ITM

42,86%

Sweeps

0,00%

TGTX Neueste Nachrichten

Zeitraum †ÄnderungÄnderung %HandelsbeginnHochNiedrigDurchsch. VolumenVWAP
18.0618.973634651642.4850.641.55307150247.40795442CS
411.5229.523321373739.0250.636.475201420542.58609429CS
1220.266.578773895830.3450.629.72204376438.7604256CS
2619.1360.904170646331.4150.626.76198846434.07746963CS
5214.0638.541666666736.4850.625.33198046133.35197378CS
15623.5487.18518518522750.66.46320267122.73455255CS
26013.1335.097567495337.4150.63.48312666719.51426001CS

TGTX - Frequently Asked Questions (FAQ)

What is the current TG Therapeutics Inc share price?
The current share price of TG Therapeutics Inc is US$ 50,54
How many TG Therapeutics Inc shares are in issue?
TG Therapeutics Inc has 141.723.008 shares in issue
What is the market cap of TG Therapeutics Inc?
The market capitalisation of TG Therapeutics Inc is USD 7,16B
What is the 1 year trading range for TG Therapeutics Inc share price?
TG Therapeutics Inc has traded in the range of US$ 25,33 to US$ 50,60 during the past year
What is the PE ratio of TG Therapeutics Inc?
The price to earnings ratio of TG Therapeutics Inc is 17,25
What is the cash to sales ratio of TG Therapeutics Inc?
The cash to sales ratio of TG Therapeutics Inc is 10,02
What is the registered address of TG Therapeutics Inc?
The registered address for TG Therapeutics Inc is 3020 Carrington Mill Blvd., Morrisville, North Carolina, 27560
What is the TG Therapeutics Inc website address?
The website address for TG Therapeutics Inc is www.tgtherapeutics.com
Which industry sector does TG Therapeutics Inc operate in?
TG Therapeutics Inc operates in the Biotechnology & Life Sciences sector

TGTX Trades

Mehr

Trades verzögert

Um Echtzeit-Trades zu erhalten, aktualisieren Sie Ihr Konto

Auf Echtzeit aktualisieren
Keine Diskussionen Gefunden.
Neuen Thread Erstellen